Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Case-Control Clinical Validation Study of a Multiplex Blood Protein Biomarker Test, IMMNOV-2, for Early Detection of Pancreatic Ductal Adenocarcinoma (PDAC) in High-Risk Patients

NCT06947382 is registered in ClinicalTrials.gov with Immunovia, Inc. as lead sponsor.

NCT NCT06947382
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06947382 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Case-Control Clinical Validation Study of a Multiplex Blood Protein Biomarker Test, IMMNOV-2, for Early Detection of Pancreatic Ductal Adenocarcinoma (PDAC) in High-Risk Patients
Lead sponsor
Immunovia, Inc.
Phase
Observational
Overall status
Completed
Start date
September 2, 2024
Completion date
January 6, 2025
Enrollment
1,066 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

cancer diagnosis, pancreatic cancer stage i, pancreatic cancer stage ii, pdac - pancreatic ductal adenocarcinoma